Abcam’s new CRISPR-Cas9 cell lines for target identification, validation and pathway discovery

Cambridge, UK, 30 January 2020 – Abcam’s new CRISPR-Cas9 knockout (KO) cell lines provide reproducible, single gene KOs that support the interrogation of the relationship between genotype and phenotype.

Obtaining high-quality KO cell lines and lysates that match specific experimental requirements can be technically challenging and time consuming, requiring months for transfection, clone isolation and screening work. Having a reliable, ready-to-use source of KO cell lines allows researchers to confidently progress target identification and validation without the need to first establish a KO cell line.

Abcam’s newly-launched collection provides the global scientific community with a wide range of KOs in commonly used immortalized cancer cell lines such as Hela and HEK293T. With an ever-expanding range of new targets and parental cell lines, selection and ordering is as easy as buying a reagent.

All KO cell lines are Sanger sequenced to confirm knockout, and many have additional Western blot data included. A wild-type positive control cell line is also available.

Abcam’s KO cell lines deliver:

• Immediate access to pre-validated CRISPR-Cas9-engineered KO cell lines derived from Hela and HEK293T
• Supports target identification, validation and pathway discovery, antibody screening and validation, compound hit identification and validation as well as disease model development
• No in-house CRISPR-Cas9 or molecular biology expertise required, saving >3 months of KO production work

Media contact: external.comms@abcam.com